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Abstract 
Background: Prostate cancer (PCa) is the most commonly diagnosed solid tumor and the second leading cancer 
death in the United States, and also one of the major cancer‑related deaths in Chinese. Androgen deprivation therapy 
(ADT) is the first line treatment for metastatic PCa. PCa ultimately relapses with subsequent ADT treatment failure and 
becomes castrate‑resistant (CR). It is important to develop effective therapies with a surrogate marker towards CR PCa.
Method: Histone deacetylase (HDAC) inhibitors were examined to determine their effects in androgen receptor (AR)/
cellular prostatic acid phosphatase (cPAcP)‑positive PCa cells, including LNCaP C‑33, C‑81, C4‑2 and C4‑2B and MDA 
PCa2b androgen‑sensitive and androgen‑independent cells, and AR/cPAcP‑negative PCa cells, including PC‑3 and DU 
145 cells. Cell growth was determined by cell number counting. Western blot analyses were carried out to determine 
AR, cPAcP and PSA protein levels.
Results: cPAcP protein level was increased by HDAC inhibitor treatment. Valproic acid, a HDAC inhibitor, suppressed 
the growth of AR/cPAcP‑positive PCa cells by over 50% in steroid‑reduced conditions, higher than on AR/cPAcP‑neg‑
ative PCa cells. Further, HDAC inhibitor pretreatments increased androgen responsiveness as demonstrated by PSA 
protein level quantitation.
Conclusion: Our results clearly demonstrate that HDAC inhibitors can induce cPAcP protein level, increase androgen 
responsiveness, and exhibit higher inhibitory activities on AR/cPAcP‑positive PCa cells than on AR/cPAcP‑negative PCa 
cells. Upon HDAC inhibitor pretreatment, PSA level was greatly elevated by androgens. This data indicates the poten‑
tial clinical importance of cPAcP serving as a useful biomarker in the identification of PCa patient sub‑population 
suitable for HDAC inhibitor treatment.
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Background
Prostate cancer is the most commonly diagnosed solid 
tumor and the second leading cancer death in United 
States. While the incidence in Chinese population is 
lower than in Western countries, it is rising rapidly and 
becomes one of the major cancer-related deaths in this 
region [1, 2]. Androgen-deprivation therapy (ADT) is the 
first line treatment for the advanced metastatic PCa by 
decreasing the production of androgens or the functions 
of AR with anti-androgen agents [3–5]. Unfortunately, 
most PCa will eventually still progress to castration-
resistant prostate cancer (CR PCa) which represents an 
aggressive and incurable phenotype after a certain time 
period of treatment [4, 6]. Although new FDA approved 
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therapies demonstrating increased survival benefits 
for CR PCa treatment exist, there are still no treatment 
modalities to inhibit the development of CR PCa [3].
Human prostatic acid phosphatase (PAcP), a 100  kDa 
glycoprotein of two subunits, is a prostate epithelium-
specific differentiation antigen: one stays intracellularly, 
the cellular form (cPAcP), and the other secrets into semi-
nal fluid, the secretory form (sPAcP), both encoded by the 
same gene [7, 8]. In normal males, circulating sPAcP activ-
ity is negligible. Interestingly, the serum activity of sPAcP 
is significantly elevated in PCa patients, especially in PCa 
patients with bone metastasis, and also correlated with 
tumor progression. sPAcP was thus utilized as a surrogate 
maker for the diagnosis and prognosis of PCa before the 
availability of prostate-specific antigen (PSA) despite the 
decreased expression of mRNA levels [9, 10]. sPAcP can 
also serve as an independent predictor of tumor recur-
rence following radical prostatectomy [7, 11]. Addition-
ally, several lines of evidence show that cPAcP may serve 
as an excellent measure to elucidate the molecular mecha-
nism of the relationship between androgens and tyrosine 
phosphorylation signaling involved in prostate cancer 
progression [8, 12–15]. cPAcP has been shown to be a 
negative growth regulator of prostate epithelia through 
its neutral protein tyrosine phosphatase (PTP) activity by 
dephosporylating p-Tyr of ErbB-2, which results in regu-
lating androgen sensitivity [5, 12, 15]. Interestingly, cPAcP 
is involved in the effect of HDAC inhibitors on PCa cell 
growth suppression via its up-regulation for ErbB-2 
dephosphorylation, and knockdown PAcP expression 
by shRNA reduces the degree of growth suppression by 
HDAC inhibitor [16]. Collectedly, cPAcP protein serves as 
a prostate epithelial differentiation marker and functions 
as a unique prostate-specific tumor suppressor [8].
Histone acetylation is regulated by a dynamic balance 
between histone acetyl transferases (HATs) and histone 
deactylases (HDACs), and involved in affecting the chro-
matin folding during gene expression [17, 18]. HDACs 
modulate transcriptional activity of hormonal receptors 
including AR, for example, by altering the stability of the 
transcriptional pre-initiation complex and/or modifying 
the chromatin structure. Many lines of evidence dem-
onstrate HDACs over-expression or close association in 
multiple cancers, including PCa [3, 19]. HDAC inhibi-
tors are epigenetic therapy agents targeting class I and/or 
class II histone deacetylases which alter not only histone 
and also non-histone protein function [6, 18]. HDAC 
inhibitors have been shown to mediate tumor cell differ-
entiation, exhibit a dramatic inhibitory effect on tumor 
cell proliferation and death [3, 20]. HDAC inhibitors have 
therefore been considered to be a novel class of cancer 
treatment agents and a number of inhibitors have been 
entered into clinical trials for PCa therapy.
A biomarker such as a measurable molecular, cellu-
lar, or genetic parameter should indicate the biological 
or pathological conditions or pharmacological response 
to the treatments. Drug discovery and development in 
cancer research is rapidly approaching personalized or 
mechanism-based targeting therapy. The application of 
a suitable biomarker in the novel treatment could bring 
various advantages, such as the increasing potency, spe-
cific tumor selectivity, reducing toxicities and side effect 
profiles, improving the quality of patient’s life. HDAC 
inhibitors may serve as a novel class of anti-cancer 
agents; to develop a selecting biomarker for patient pop-
ulation who are suitable to HDAC inhibitor treatment 
requires further identification. In our previous study, we 
investigated the molecular target by HDAC inhibitors for 
exploring their potential of CR PCa therapy. We found 
that cPAcP expression is involved in growth suppression 
by HDAC inhibitors in AR-positive PCa cells, and HDAC 
inhibitor pre-treatment could increase androgen respon-
siveness of those PCa cells [16].
In this study, we tested the hypothesis that cPAcP can 
serve as a useful biomarker for identifying patients sen-
sitive to HDACi treatments. We analyzed six different 
HDAC inhibitors which have shown inhibitory activities 
on tumor cell proliferation and/or viability or entered 
in various clinical trials, including valproic acid (VPA), 
sodium butyrate (NaB), suberoylanilide hydroxamic acid 
(SAHA), PxD 101, MS-275 and AR-42 [6, 16, 20–29] on 
six AR/cPAcP-positive and four AR/cPAcP-negative PCa 
cell lines. Our data provide strong evidence for the role of 
cPAcP expression in various HDAC inhibitors treatment 
in PCa cells. HDAC inhibitor treatment elevated cPAcP 
expression level and increased the androgen responsive-
ness of AR/cPAcP-positive PCa cells as shown by ele-
vated PSA protein levels. Importantly, in steroid-reduced 
conditions mimicking clinical androgen deprivation ther-
apy, AR/cPAcP-positive PCa cells were more sensitive to 
inhibitory efficiency of HDAC inhibitors treatment than 
AR/cPAcP-negative PCa cells. These results have impor-
tant clinical impacts on identifying a useful biomarker for 
HDAC inhibitors toward advanced CR PCa treatment 
and also on predicting clinical treatment outcome.
Results and discussion
Cellular prostatic acid phosphatase (cPAcP) is a unique 
prostate-specific tumor suppressor and its loss of expres-
sion is associated with prostate carcinogenesis [8]. The 
data also revealed that cPAcP is involved in regulating 
androgen-stimulated PCa cell growth, and its expres-
sion is associated with androgen-sensitive cell prolifera-
tion [7, 16]. Previously, we identified that cPAcP is one 
of molecular targets by HDAC inhibitors in PCa growth 
suppression. In HDAC inhibitor-treated AR-positive PCa 
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cells, cPAcP is elevated and cell growth is suppressed; 
conversely, knockdown cPAcP expression by shRNA 
reduces the degree of growth suppression by HDAC 
inhibitors [16]. Furthermore, cPAcP in addition to AR 
plays a critical role in regulating androgen sensitivity of 
PCa cell proliferation. While AR is essential to andro-
gen sensitivity; the presence of AR alone is not sufficient 
for androgen responsiveness of growth stimulation. For 
example, CR PCa cells still express functional AR but 
are androgen unresponsive. Instead, the expression of 
cPAcP in those cells is associated with androgen sensitiv-
ity. Since cPAcP expression is responsive to but not regu-
lated by androgens, cPAcP level is not consistent with AR 
level. Importantly, upon VPA pretreatment, the androgen 
responsiveness of cells was increased, higher than con-
trol cells. As a clinical correlation, we selected cPAcP as a 
surrogate marker and further explored the role of cPAcP 
expression in PCa cell growth suppression by various 
HDAC inhibitors and examined whether HDAC inhibi-
tors treatment will indeed alter androgen responsiveness 
of different PCa cells.
First, we analyzed the basal level of AR, PAcP and PSA 
proteins in different PCa cell lines. As shown in Figure 1, 
in regular culture condition, MDA PCa2b AS and AI cells, 
and LNCaP C-33, C-81, C4-2 and C4-2B cells all express 
AR protein. Among them, LNCaP cells had an overall 
higher levels of AR protein than MDA PCa2b cells, and 
LNCaP C-33 cells expressed the highest AR protein level 
among these cells examined (Figure  1), correlating with 
the degree of androgen-stimulated cell growth (data 
not shown). On the contrary, MDA PCa2b cells express 
higher levels of cPAcP than LNCaP cells (Figure  1) and 
have slower cell proliferation [30]. Furthermore, in MDA 
PCa2b and LNCaP cell models, cPAcP level decreased in 
AI cells, lower than that in the corresponding AS cells, 
respectively. The low PAcP level in AI LNCaP C-81, C4-2 
and C4-2B could be seen upon prolonged exposure (data 
not shown). The PSA protein level is also decreased in 
AI cells. In comparison, PC-3 and DU 145 cells do not 
express a detectable level of AR, PAcP and PSA proteins 
(Figure 1) despite prolonged exposure (data not shown).
We determined the effect of HDAC inhibitor on 
cPAcP protein level in AR-positive PCa cells and exam-
ined their relationship since cPAcP protein functions as 
a tumor suppressor in PCa cells. We first examined VPA 
effect on cPAcP protein level. As shown in Figure 2a–c, 
upon VPA treatment, cPAcP protein levels were greatly 
elevated in LNCaP C-33 and C4-2B cells, compared with 
control cells received the solvent alone (Figure 2a, b, Lane 
#3 vs. #1, right panel), which were decreased by subse-
quent DHT treatment (Figure 2a, b, Lane #4 vs. #3, right 
panel). cPAcP protein level had only a slight elevation in 
VPA-treated MDA PCa2b-AS cells (Figure  2c, Lane #3 
vs. #1, right panel), which could be in part due to a very 
high basal level of cPAcP protein in those cells (Figure 1). 
Similar phenomenon was observed in LNCaP C-81, C4-2 
and MDA PCa2B AI PCa cells (data not shown; [16]). 
Therefore, the observations on cPAcP protein levels that 
are increased in all VPA-pretreated PCa cells and then 
decreased by DHT treatment are inversely correlated 
with cell growth (Figure 2, Column #1 vs. #3, #3 vs. #4, 
left panel).
Since androgen sensitivity is an important clinical 
phenomenon; we examined VPA effect on the androgen 
responsiveness. Importantly, the PSA level was greatly 
elevated by 10  nM DHT in VPA-pretreated LNCaP cell 
lines by over 18-fold, higher than that of control cells 
without VPA-pretreatment with about fourfold increase 
(Figure  2a, b, Lane #4 vs. #2, right panel). In VPA-pre-
treated MDA PCa2b AS cells, PSA protein level was 
greatly elevated, which is further increased upon DHT 
treatment (Figure 2c, Lane #4 vs. #3, right panel); despite 
the fact that DHT alone only had a marginal effect on 
PSA protein level in the absence of VPA pretreatment, 
the similar trends were observed in LNCaP C-81, C4-2 
and MDA PCa2B AI PCa cell lines (data not shown; [16]). 
In summary, our data show that VPA pretreatment can 
increase the degree of androgen sensitivity in cell prolif-
eration by cell number counting and PSA protein level, 
an androgen-regulated marker, despite that in MDA 
PCa2b AS cells, VPA pretreatment only greatly enhanced 
DHT-increased PSA level (Figure 2c, Lane #3 vs. #4, right 
panel) but not cell growth (Figure 2c, Column #3 vs. #4, 
left panel). Furthermore, cPAcP protein level was indeed 
elevated by VPA treatment and then diminished by sub-
sequent DHT treatment (Figure  2, Lane #3 vs. #4, right 
panels). Since VPA pretreatment greatly enhances DHT-
upregulated PSA level, the data indicate that VPA can 
Figure 1 The basal expression levels of AR, cPAcP and PSA were 
determined in different PCa cell lines. LNCaP C‑33/C‑81, LNCaP C4‑2/
C4‑2B, MDA PCa2B AS/AI, PC‑3 and DU 145 cells that were plated in 
regular medium for 3 days and then changed with fresh medium for 
1 day. The cells were harvested and the total protein was subjected to 
western blot analyses of functional proteins expression. β‑Actin was 
analyzed and used as a loading control.
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Figure 2 Effect of VPA on androgen responsiveness of PCa cell lines. a LNCaP C‑33; b LNCaP C4‑2B; c MDA PCa2B AS cells were seeded in 6‑wells 
plate and then treated with 1 mM VPA or solvent for 48 h. Cell were then maintained in a steroid‑reduced medium with or without 10 nM DHT for 
2 days. Total cell number was counted. The ratio of cell growth was calculated by normalizing the cell number to that of control cells (column #1, left 
panel, n = 3×2). Total cell lysate proteins from 3‑day DHT treatment were analyzed for cPAcP, PSA, AR protein. β‑Actin was analyzed and used as a 
loading control (right panel).
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increase androgen responsiveness of AR-positive PCa 
cells.
We examined whether other HDAC inhibitors could 
similarly enhance the androgen responsiveness of PCa 
cells. LNCaP C-81 cells were used as the model for 
HDAC inhibitors pretreatment since C-81 cells exhibit 
many biochemical properties of CR PCa cells (16, 31, 32). 
C-81 cells were treated with HDAC inhibitors including 
NaB, SAHA, PxD101, MS-275 and AR42. Results of west-
ern blot analyses showed that cPAcP protein including 
the 38 kDa intermediate form and 50 kDa mature form 
were greatly elevated by all HDAC inhibitor treatments 
(Figure 3a–e, Lane #3 vs. #1, right panel) and were dimin-
ished by subsequently 1 and 10 nM DHT treatments, fol-
lowing the dose-dependent manner (Figure  3a, Lane #4 
vs. #3, right panel; Figure 3b–e, Lane #5, 6 vs. Lane #4, 
right panel). Further analyses on Figures  2 and 3 reveal 
that the efficacy of HDAC inhibitor’s growth suppression 
is at least in part correlated with the degree of induced 
expression of cPAcP in addition to cPAcP basal level.
Furthermore, we validated DHT responsiveness by ana-
lyzing PSA protein level followed by semi-quantification 
in HDAC inhibitors-pretreated cells. In absence of DHT, 
PSA basal levels were greatly elevated by SAHA, PxD 
101 and MS-275 treatments, and slightly increased in 
AR42-treated cells, but not significantly elevated in NaB-
treated cells, respectively (Figure  3b–e, Lane #4 vs. #1; 
Figure 3a, Lane #3 vs. #1, right panel). Importantly, PSA 
expression levels were greatly elevated by 10 nM DHT in 
all HDAC inhibitor-pretreated cells by up to 12-fold of 
that in control cells without HDAC inhibitor pretreat-
ment (Figure 3a, Lane #4 vs. #2; Figure 3b–e, Lane #6 vs. 
#3 right panel). However, the growth stimulation by DHT 
was only marginally increased in those HDAC inhibitors-
pretreated cells comparing with control cells and only 
significantly increased in MS-275 and AR42 pretreated 
cells (Figure  3a, Column #4 vs. #3; Figure  3b–e, Col-
umn #5, 6 vs. #4, left panel). The data collectively indi-
cate that HDAC inhibitors exhibit the significant efficacy 
of growth suppression and can enhance the androgen 
responsiveness of PSA levels. Nevertheless, the effect of 
HDAC inhibitors pretreatment on DHT-stimulated cell 
growth requires further investigation.
Since the expression of cPAcP correlates with growth 
suppression by HDAC inhibitors, we investigated 
whether cPAcP protein level can serve as a useful bio-
marker of identifying the PCa patient sub-population 
who is potentially responsive to HDAC inhibitors treat-
ment. To mimic the clinical situation of chemotherapy 
under androgen ablation conditions, cell growth sup-
pression was determined in steroid-reduced (SR) condi-
tions. Six AR/cPAcP-positive PCa cell lines and four AR/
cPAcP-negative PCa cell lines including NE 1–3 and NE 
1–8 cells, two neuroendocrine prostate cancer cell lines, 
were examined. After 2  days of VPA treatment, all PCa 
cells were maintained in SR medium for 72  h. Interest-
ingly, the growth of those AR/cPAcP-positive PCa cells 
were in general significantly decreased by VPA treatment 
with more than 50% suppression; while the growth of 
AR/cPAcP-negative PCa cells was suppressed by less than 
50% (Figure 4). The data indicate that cPAcP can poten-
tially serve as a biomarker for HDAC inhibitor treatment 
with clinical benefits. Those patients can be more sensi-
tive to HDAC inhibitor treatment, i.e., higher growth 
suppression and enhanced androgen responsiveness.
Conclusion
In summary, the results of our study clearly show that 
in all HDAC inhibitors-treated AR/cPAcP-positive PCa 
cells, growth suppression by HDAC inhibitors is associ-
ated with elevated cPAcP protein level, and the androgen 
responsiveness of those PCa cells is also enhanced. PCa 
cells which exhibit endogenous cPAcP expression are 
more sensitive to HDAC inhibitors as shown by higher 
inhibitory efficiency with more than 50% compared with 
that of PCa without cPAcP expression by HDAC inhibi-
tor treatments (Figure 4). Our data reveal that cPAcP can 
serve as a biomarker for identifying PCa patients who 
are sensitive to be treated by HDAC inhibitors. cPAcP 
can thus serve as a surrogate marker in PCa therapy, 
predicting clinical outcome to decrease the medical 
resources waste and improve the treatment efficacy. Fur-
thermore, HDAC inhibitor-treated patients may re-gain 
their androgen responsiveness and thus are suitable to 
continue ADT treatment. HDAC inhibitors significantly 
increase PSA protein level while inhibit PCa cell prolif-
eration, serum PSA cannot serve as a suitable marker 




RPMI 1640 medium, gentamicin and trypsin/EDTA 
reagents were purchased from Invitrogen Corporation 
(Carlsbad, CA, USA). Fetal bovine serum (FBS), char-
coal/dextran-treated, certified FBS was from Atlanta 
Biologicals (Lawrenceville, GA, USA). Acrylamide, pro-
tein molecular weight standard markers and Protein 
Estimation Kit were obtained from Bio-Rad (Hercules, 
CA, USA). The ECL reagent kit was purchased from 
Pierce Biotechnology Inc. (Rockford, IL, USA). Histone 
deacetylase inhibitors including sodium butyrate (NaB), 
valproic acid (VPA), 5α-dihydrotestosterone (DHT) and 
anti-β-Actin Ab (AC-15) were from Sigma (St Louis, MO, 
USA). Other HDAC inhibitors, including suberoylanilide 
hydroxamic acid (SAHA), AR42 and MS-275, were kindly 
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Figure 3 Effects of different HDAC inhibitors on androgen responsiveness of PCa cells. LNCaP C‑81 cells were plated in 6‑wells plate and then 
treated with a 1 mM NaB; b 2.5 µM SAHA; c 2.5 µM PxD101; d 1.0 µM MS‑275; e 0.5 µM AR42 or solvent alone for 48 h. Cell were then maintained in 
a steroid‑reduced medium with or without 1 and 10 nM DHT for 3 days. Total cell number was counted. The ratio of cell growth was calculated by 
normalizing the cell number to that of control cells (column #1, left panel, n = 3×2). Total cell lysate proteins were analyzed for cPAcP, PSA and AR 
protein. β‑Actin was analyzed and used as a loading control (right panel).
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provided by Dr. Ching-Shih Chen at the Ohio State Uni-
versity Comprehensive Cancer Center (Columbus, OH, 
USA). PxD101 was from Dr. Jue Wang at Medical Oncol-
ogy section, University of Nebraska Medical Center 
(Omaha, NE, USA). Rabbit anti-human PAcP Ab (ATM-
3) has been described previously [14, 15]. The respective 
Abs against androgen receptor (AR) and PSA were from 
Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Cell culture
Human prostate carcinoma cell lines including LNCaP, 
MDA PCa2b, PC-3 and DU 145 cells were originally 
purchased from the American Type Culture Collection 
(Rockville, MD, USA). LNCaP C4-2 and C4-2B cells were 
purchased from DIANON Company (Oklahoma City, OK, 
USA). LNCaP C-33/C-81, PC-3 and DU 145 cells were rou-
tinely maintained in the regular medium, i.e., phenol red-
positive RPMI 1640 medium supplemented with 5% FBS, 
2  mM glutamine and 50  µg/ml gentamicin. MDA PCa2b 
cells were cultured in BRFF-HPC1 medium containing 20% 
FBS, 2  mM glutamine and 50  µg/ml gentamicin. LNCaP 
C4-2 and C4-2B cells were grown in DMEM/F12 medium 
with 10% FBS, 2  mM glutamine, 50  µg/ml gentamicin, 
1 mM sodium pyruvate, 2× vitamin C and 1× MEM non-
essential amino acid. Cells were split once a week by trypsi-
nization, which was defined as one passage.
The LNCaP PCa cell progression model was origi-
nally described by Lin et  al. [31] and further character-
ized by Igawa et al. [32] with passage number less than 35 
defined as C-33, passage numbers between 80 and 120 as 
C-81 cells. LNCaP C-81 cells exhibit many biochemical 
properties similar to the phenotype of advanced CR PCa, 
including the intracrine growth regulation, PSA secretion 
and rapid cell proliferation under steroid-deprived con-
ditions. LNCaP C4-2/C4-2B cells also exhibit androgen 
independency of growth [33]. Similarly, MDA PCa2b-AI 
cells, the high passage MDA PCa2b cells, exhibit andro-
gen-independent proliferation as described [12, 34, 35]. 
In this set of experiments, the passage numbers of MDA 
PCa2b-AI cells were between about 110 and 125.
Effect of HDAC inhibitor pretreatment on the androgen 
responsiveness and cell growth suppression of PCa cell 
lines
Various PCa cell lines, including LNCaP C-33/C-81, 
LNCaP C4-2/C4-2B and MDA PCa2b AS/AI cells were 
plated with 3  ×  104, 3  ×  104 and 1  ×  105 cells/well, 
respectively, in 6-well plates in regular medium for 3 days 
and then treated with 1 mM VPA or different concentra-
tions of HDAC inhibitors as specified in each experiment 
for 2 days. Control cells were treated with solvent alone. 
Subsequently, cells were maintained in a steroid-reduced 
medium minus or plus 1 and 10 nM DHT for 2 days. Cells 
were harvested and cell numbers were counted using 
a Cellometer Auto T4 Image-based cell counter (Nex-
celom Bioscience). All experiments were performed in 
triplicate and repeated at least twice. Results shown were 
an average or a representative from two or three sets of 
independent experiments. Cells were lysed for analyzing 
cPAcP, AR and PSA protein expression. β-Actin was used 
as a loading control.
To determine the effect of cPAcP on PCa cell growth 
suppression by HDAC inhibitors, LNCaP (C-33/C-81, 
C4-2/C4-2B), MDA PCa2B AS/AI, NE1-3/1-8, PC-3 and 
DU145 PCa cells were plated in 6-well plates in regular 
medium for 3  days, treated with 1  mM VPA for 2  days 
and then maintained in steroid-reduced medium for 
3 days. Control cells were treated with solvent alone. The 
cell numbers were counted. The ratio of cell growth was 
calculated by normalizing the number of experimental 
cells to that of control cells.
Immunoblotting
For analyzing cellular protein levels, subconfluent cells 
were harvested by scraping. The cell pellet was rinsed 
with ice-cold 20 mM HEPES-buffered saline (pH 7.0) and 
then lysed in ice-cold cell lysis buffer (20 mM Tris–HCl, 
pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40) 
containing protease and phosphatase inhibitors and the 
total lysate protein was prepared upon centrifugation. An 
aliquot of total cellular lysate having 50–120  µg protein 
was subjected to electrophoresis on SDS–polyacryla-
mide gels (7.5–12% acrylamide) and then transferred 
to nitrocellulose membrane for western blot analyses. 
The membrane filter was blocked by 5% skim milk and 
Figure 4 The growth inhibition of VPA treatment on various PCa 
cells. LNCaP C‑33/C‑81, LNCaP C4‑2/C4‑2B, MDA PCa2B AS/AI, NE 
1‑3/1‑8, PC‑3 and DU 145 PCa cell lines were plated in 6‑wells plates 
and then treated with 1 mM VPA or solvent for 48 h. Cells were then 
maintained in a steroid‑reduced medium for 3 days. Total cell number 
was counted. The ratio of cell growth was calculated by normalizing 
the cell number to that of control cells (n = 3×2).
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subsequently incubated with appropriate primary and 
secondary Ab. The proteins of interest were visualized by 
an ECL detection system. For re-probing, the membranes 
were stripped with a stripping buffer for 30 min at 50°C, 
blocked and re-hybridized with specific Abs [16].
Statistical analysis
Each experiment was performed in duplicate or tripli-
cates and repeated at least twice as independent experi-
ments, as specified in each figure legend or experiment 
design, and the mean and standard error values were cal-
culated. The significance of difference (p value) was cal-
culated using independent Student t test and the p value 
less than 0.05 was considered as significant.
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